The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1 × VEGF bsAb) in patients with advanced solid tumors.
 
Siqing Fu
Research Funding - Abbisko (Inst); Antengene (Inst); BeiGene (Inst); BeyondSpring Pharmaceuticals (Inst); Biotheus (Inst); Boehringer Ingelheim (Inst); Clinical and Translational Science Award Grant (CTSA) 1UM1TR0045906 (Inst); Coherent Biopharma (Inst); CPRIT Precision Oncology Decision Support Core (RP150535) (Inst); Crossignal (Inst); CUE Biopharma (Inst); DEKA Biosciences (Inst); Exelis (Inst); Exelis (Inst); Fore Biotherapeutics (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); Jazz Pharmaceuticals (Inst); K-Group Beta (Inst); Lantern Pharma (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); PharmaMar (Inst); Pionyr (Inst); PureTech (Inst); Qurgen Inc. (Inst); Sellas Life Sciences (Inst); Shanghai Huaota Biopharmaceutical (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Tigermed Group (Inst); TransCode Therapeutics, Inc. (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)
 
David Pinato
Honoraria - Avammune; Boston Scientific; Bristol-Myers Squibb; Da Volterra; Galapagos NV; Lift Biosciences; Mursla Bio; Parabilis; Roche/Genentech; Starpharma; TERUMO
Consulting or Advisory Role - AstraZeneca; Da Volterra; EISAI; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Boston Scientific; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley
 
Muhammad Khattak
Honoraria - Evaxion Biotech
Consulting or Advisory Role - Moderna Therapeutics
Travel, Accommodations, Expenses - Evaxion Biotech; Moderna Therapeutics; Pierre Fabre
 
Rohit Joshi
Honoraria - Bristol-Myers Squibb; Gilead Sciences; Ipsen; Merck Sharp & Dohme; Pfizer; Pfizer/EMD Serono; Roche
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Roche
Speakers' Bureau - Gilead Sciences
Travel, Accommodations, Expenses - Novartis
 
Christoph Oing
Honoraria - Springer Nature publishing group
Consulting or Advisory Role - Sandoz
Research Funding - BioNTech (Inst); GlaxoSmithKline (Inst)
 
Alexa Childs
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
Fiona Thistlethwaite
Consulting or Advisory Role - AstraZeneca; Grey Wolf Therapeutics; Immatics; Oncobayes (Inst); T-Knife; Waypoint Bio
Research Funding - Achilles Therapeutics (Inst); Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Corbus Pharmaceuticals (Inst); Crescendo Bioscience (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Grey Wolf Therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Kymab (Inst); Leucid Bio (Inst); Moderna Therapeutics (Inst); NovalGen (Inst); Nucana (Inst); Oxford VacMedix (Inst); Roche (Inst); RS Oncology (Inst); Sanofi (Inst); Seagen (Inst); T-Knife (Inst); Takeda (Inst); UCB (Inst); Zymeworks (Inst)
 
Pavlina Spiliopoulou
Consulting or Advisory Role - Iovance Biotherapeutics
Speakers' Bureau - Bristol-Myers Squibb
Other Relationship - Access Pharmaceuticals (Inst); BioNTech (Inst); C4 Therapeutics (Inst); Corbus Pharmaceuticals (Inst); IDEAYA Biosciences (Inst); Immatics (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Microbiotica (Inst); Moderna Therapeutics (Inst); Mythic Therapeutics (Inst); Replimune (Inst); Verastem (Inst)
 
Amy Quinton
No Relationships to Disclose
 
Lalit Pallan
Consulting or Advisory Role - Iovance Biotherapeutics; Sun Pharma
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Sun Pharma
 
James Larkin
Honoraria - Bristol-Myers Squibb; Cancer Research UK; Eisai; GlaxoSmithKline; Gynavax; Incyte; iOnctura; Merck Serono; Novartis; Pfizer; Roche; touchEXPERTS; touchIME
Consulting or Advisory Role - Apple Tree Partners; Boston Biomedical; Bristol-Myers Squibb; Eisai; Immunocore; Incyte; iOnctura; Iovance Biotherapeutics; Merck Serono; MSD Oncology; Novartis; Pfizer; YKT Corporation
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Roche; ESMO; GlaxoSmithKline; Roche/Genentech
 
Manish Patel
Leadership - ION Pharma
Consulting or Advisory Role - Accutar Biotech; Daiichi Sankyo/UCB Japan; Johnson & Johnson/Janssen; Kura Oncology; Mitsubishi Tanabe Pharma; shivanka Research
Research Funding - Abbvie (Inst); Abdera Thereapeutics (Inst); Accutar Biotech (Inst); Adagene (Inst); Agenus (Inst); Allorion Therapeutics (Inst); Apollo (Inst); Artios (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avenzo (Inst); BioNTech SE (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Conjupro Biotherapeutics (Inst); Cullinan Oncology (Inst); cyteir (Inst); D3 Bio (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Georgiamune (Inst); Hotspot Therapeutics (Inst); Immune-Onc Therapeutics (Inst); Immunitas (Inst); Immunogen (Inst); Incyte (Inst); Janssen (Inst); Kineta (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); Medlink (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); nurix (Inst); Olema Oncology (Inst); OnCusp Therapeutics (Inst); Pfizer (Inst); Prelude Therapeutics (Inst); Ribon Therapeutics (Inst); Seven and Eight Biopharmaceuticals (Inst); Step Pharma (Inst); Sutro Biopharma (Inst); Syndax (Inst); Systimmune (Inst); TeneoBio (Inst); Vividion Therapeutics (Inst); Zai Lab (Inst); Zymeworks (Inst)
 
Kyriakos Papadopoulos
Consulting or Advisory Role - AADi; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Alnylam (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Bristol-Myers Squibb/Celgene (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-star (Inst); Frontier Medicines (Inst); Genmab (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Parabilis Medicines (Inst); Pfizer (Inst); PharmaMar (Inst); Regeneron (Inst); Revolution Medicines (Inst); Sensei Biotherapeutics (Inst); Storm Therapeutics (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
William McKean
Consulting or Advisory Role - Recursion Pharmaceuticals
 
Monica Chen
Stock and Other Ownership Interests - docs; FIGS; Nordisk; Quest Diagnostics
Consulting or Advisory Role - Candel Therapeutics
Research Funding - ASCO; NIH
Travel, Accommodations, Expenses - AACR; ASCO
 
Sreenivasa Chandana
Leadership - The Cancer & Hematology Centers
Consulting or Advisory Role - AstraZeneca; IPSEN; Novocure
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); BioNTech SE (Inst); BMS (Inst); Cardiff Oncology (Inst); Chugai Pharma (Inst); Corcept Therapeutics (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Exelixis (Inst); Genentech/Roche (Inst); Halda Therapeutics (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Johnson & Johnson/Janssen (Inst); Medlink (Inst); Merck (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Rondo Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Zymeworks (Inst)
 
Christina Trück
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
 
Huyuan Yang
Employment - BioNTech SE
Stock and Other Ownership Interests - BioNTech SE
Speakers' Bureau - BioNTech SE
Travel, Accommodations, Expenses - BioNTech SE
 
Raoul Tibes
Employment - BioNTech
Stock and Other Ownership Interests - BioNTech
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; AstraZeneca; AstraZeneca/UK; Aulos Bioscience; Bayer; BioNTech SE; Boehringer Ingelheim; Bristol Myers Squibb; Byondis; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Iovance Biotherapeutics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics; Strand Therapeutics